AU2004281750A1 - Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms - Google Patents

Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms Download PDF

Info

Publication number: AU2004281750A1
Authority: AU; Australia
Prior art keywords: ethyl; piperazinyl; cyclohexanol; reuptake inhibitor; methyl
Prior art date: 2003-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

AU2004281750A

Other languages

English (en)

Inventor

Chad Edward Beyer

Darlene Coleman Deecher

Liza Leventhal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wyeth LLC

Original Assignee

Wyeth LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-14

Filing date

2004-10-13

Publication date

2005-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34468478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004281750(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-10-14 Priority claimed from US10/685,812 external-priority patent/US20040152710A1/en

2004-10-12 Priority claimed from US10/962,897 external-priority patent/US20050130987A1/en

2004-10-13 Application filed by Wyeth LLC filed Critical Wyeth LLC

2005-04-28 Publication of AU2004281750A1 publication Critical patent/AU2004281750A1/en

Status Withdrawn legal-status Critical Current

Links

230000001457 vasomotor Effects 0.000 title claims description 37
208000024891 symptom Diseases 0.000 title claims description 35
238000011282 treatment Methods 0.000 title claims description 27
239000005557 antagonist Substances 0.000 title description 31
230000001800 adrenalinergic effect Effects 0.000 title description 5
239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 157
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 156
150000003839 salts Chemical class 0.000 claims description 78
239000002464 receptor antagonist Substances 0.000 claims description 74
229940044551 receptor antagonist Drugs 0.000 claims description 74
229940126570 serotonin reuptake inhibitor Drugs 0.000 claims description 74
150000001875 compounds Chemical class 0.000 claims description 72
238000000034 method Methods 0.000 claims description 57
239000003772 serotonin uptake inhibitor Substances 0.000 claims description 50
UXABARREKCJULM-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-ethylimidazole Chemical compound CCN1C=CN=C1CC1OC2=CC=CC=C2OC1 UXABARREKCJULM-UHFFFAOYSA-N 0.000 claims description 41
239000000203 mixture Substances 0.000 claims description 41
229950008608 imiloxan Drugs 0.000 claims description 37
230000000694 effects Effects 0.000 claims description 36
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 32
239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 31
206010060800 Hot flush Diseases 0.000 claims description 30
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 30
239000008194 pharmaceutical composition Substances 0.000 claims description 27
230000009977 dual effect Effects 0.000 claims description 21
239000004480 active ingredient Substances 0.000 claims description 20
239000003814 drug Substances 0.000 claims description 20
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 17
239000003937 drug carrier Substances 0.000 claims description 17
229960003914 desipramine Drugs 0.000 claims description 13
-1 2,3-dihydro-1,4 benzodioxin-2-yl Chemical group 0.000 claims description 11
125000004193 piperazinyl group Chemical group 0.000 claims description 11
DXPRUAWQWPNHBR-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-1-(1-ethylimidazol-2-yl)ethanone Chemical group CCN1C=CN=C1C(=O)CC1OC2=CC=CC=C2OC1 DXPRUAWQWPNHBR-UHFFFAOYSA-N 0.000 claims description 8
KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims description 8
229960004688 venlafaxine Drugs 0.000 claims description 8
GRUIIAQNNWQJPW-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-(4-methylpiperazin-1-yl)ethyl]cyclohexan-1-ol Chemical compound C1CN(C)CCN1CC(C1(O)CCCCC1)C1=CC=CC(Cl)=C1 GRUIIAQNNWQJPW-UHFFFAOYSA-N 0.000 claims description 7
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 7
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 4
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 4
PZQVDLYPNAADGQ-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-piperazin-1-ylethyl]cyclohexan-1-ol Chemical compound C1CNCCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 PZQVDLYPNAADGQ-UHFFFAOYSA-N 0.000 claims description 4
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 4
229960002519 amoxapine Drugs 0.000 claims description 4
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims description 4
VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 4
229960002430 atomoxetine Drugs 0.000 claims description 4
229960001623 desvenlafaxine Drugs 0.000 claims description 4
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 4
229960005426 doxepin Drugs 0.000 claims description 4
229960002866 duloxetine Drugs 0.000 claims description 4
229960004090 maprotiline Drugs 0.000 claims description 4
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
229960000600 milnacipran Drugs 0.000 claims description 4
ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 claims description 4
229950004211 nisoxetine Drugs 0.000 claims description 4
229960003770 reboxetine Drugs 0.000 claims description 4
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims description 4
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 4
YUTGLCAFRPAGFA-UHFFFAOYSA-N 1-[2-(dimethylamino)-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexan-1-ol Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=CC(C(F)(F)F)=C1 YUTGLCAFRPAGFA-UHFFFAOYSA-N 0.000 claims description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
JFNKXGOEOQCXDM-UHFFFAOYSA-N 2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4,4-dimethylisoquinoline-1,3-dione Chemical compound COC1=CC=CC=C1N1CCN(CCN2C(C(C)(C)C3=CC=CC=C3C2=O)=O)CC1 JFNKXGOEOQCXDM-UHFFFAOYSA-N 0.000 claims 12
YGOUOBPKDDZCPL-UHFFFAOYSA-N 1-[1-(3-fluorophenyl)-2-(4-methylpiperazin-1-yl)ethyl]cyclohexan-1-ol Chemical compound C1CN(C)CCN1CC(C1(O)CCCCC1)C1=CC=CC(F)=C1 YGOUOBPKDDZCPL-UHFFFAOYSA-N 0.000 claims 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
ZUFCXVFSSJFSOT-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexan-1-ol Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=CC(Cl)=C1 ZUFCXVFSSJFSOT-UHFFFAOYSA-N 0.000 claims 3
DJYRRZYQEUBHIZ-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-[4-(3-chlorophenyl)piperazin-1-yl]ethyl]cyclohexan-1-ol Chemical compound C1CN(C=2C=C(Cl)C=CC=2)CCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 DJYRRZYQEUBHIZ-UHFFFAOYSA-N 0.000 claims 3
SOQWNSFAQIWXJL-UHFFFAOYSA-N 1-[2-(4-benzylpiperazin-1-yl)-1-(4-fluorophenyl)ethyl]cyclohexan-1-ol Chemical compound C1CN(CC=2C=CC=CC=2)CCN1CC(C=1C=CC(F)=CC=1)C1(O)CCCCC1 SOQWNSFAQIWXJL-UHFFFAOYSA-N 0.000 claims 3
ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 claims 3
LGRZVDOIDOOMRO-UHFFFAOYSA-N 1-[2-(4-methylpiperazin-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexan-1-ol Chemical compound C1CN(C)CCN1CC(C1(O)CCCCC1)C1=CC=CC(C(F)(F)F)=C1 LGRZVDOIDOOMRO-UHFFFAOYSA-N 0.000 claims 2
BUCJHJXFXUZJHL-UHFFFAOYSA-N 1-ethylcyclohexan-1-ol Chemical compound CCC1(O)CCCCC1 BUCJHJXFXUZJHL-UHFFFAOYSA-N 0.000 claims 2
IURZWTOXSOOJPK-UHFFFAOYSA-N 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclohexan-1-ol Chemical compound COC1=CC=CC(C(CN2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)C2(O)CCCCC2)=C1 IURZWTOXSOOJPK-UHFFFAOYSA-N 0.000 claims 1
102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 claims 1
101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 claims 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 24
102100030140 Thiosulfate:glutathione sulfurtransferase Human genes 0.000 description 24
229960002748 norepinephrine Drugs 0.000 description 24
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 24
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
241000700159 Rattus Species 0.000 description 17
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 17
229960004127 naloxone Drugs 0.000 description 17
241001465754 Metazoa Species 0.000 description 13
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 13
238000001690 micro-dialysis Methods 0.000 description 11
239000000262 estrogen Substances 0.000 description 10
229940011871 estrogen Drugs 0.000 description 10
239000007788 liquid Substances 0.000 description 10
210000003169 central nervous system Anatomy 0.000 description 9
230000001331 thermoregulatory effect Effects 0.000 description 9
239000003981 vehicle Substances 0.000 description 9
210000003016 hypothalamus Anatomy 0.000 description 8
229920000609 methyl cellulose Polymers 0.000 description 8
239000001923 methylcellulose Substances 0.000 description 8
235000010981 methylcellulose Nutrition 0.000 description 8
229960005181 morphine Drugs 0.000 description 8
210000001428 peripheral nervous system Anatomy 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
229940079593 drug Drugs 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
230000000966 norepinephrine reuptake Effects 0.000 description 7
229920000136 polysorbate Polymers 0.000 description 7
229940002612 prodrug Drugs 0.000 description 7
239000000651 prodrug Substances 0.000 description 7
239000000523 sample Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
206010006187 Breast cancer Diseases 0.000 description 6
208000026310 Breast neoplasm Diseases 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
230000004064 dysfunction Effects 0.000 description 6
230000009245 menopause Effects 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
239000000969 carrier Substances 0.000 description 5
230000008859 change Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000002648 combination therapy Methods 0.000 description 5
238000007429 general method Methods 0.000 description 5
239000000843 powder Substances 0.000 description 5
238000011552 rat model Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229940090044 injection Drugs 0.000 description 4
238000002347 injection Methods 0.000 description 4
206010029410 night sweats Diseases 0.000 description 4
230000036565 night sweats Effects 0.000 description 4
210000003814 preoptic area Anatomy 0.000 description 4
150000003384 small molecules Chemical class 0.000 description 4
108010078791 Carrier Proteins Proteins 0.000 description 3
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229960002896 clonidine Drugs 0.000 description 3
230000007423 decrease Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
229960003299 ketamine Drugs 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
230000001722 neurochemical effect Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
238000009806 oophorectomy Methods 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
230000000697 serotonin reuptake Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000035900 sweating Effects 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
206010003439 Artificial menopause Diseases 0.000 description 2
238000012935 Averaging Methods 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000033830 Hot Flashes Diseases 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
206010029216 Nervousness Diseases 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
241000233805 Phoenix Species 0.000 description 2
208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
208000010340 Sleep Deprivation Diseases 0.000 description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
239000003098 androgen Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000000133 brain stem Anatomy 0.000 description 2
150000001722 carbon compounds Chemical class 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000009109 curative therapy Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
230000003467 diminishing effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
230000035558 fertility Effects 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
229960002464 fluoxetine Drugs 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
229960003132 halothane Drugs 0.000 description 2
230000013632 homeostatic process Effects 0.000 description 2
238000001794 hormone therapy Methods 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000036512 infertility Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
206010022437 insomnia Diseases 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000007915 intraurethral administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000002997 ophthalmic solution Substances 0.000 description 2
229940054534 ophthalmic solution Drugs 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
238000002638 palliative care Methods 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
206010036601 premature menopause Diseases 0.000 description 2
230000002265 prevention Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
230000028016 temperature homeostasis Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 2
229960000317 yohimbine Drugs 0.000 description 2
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
SAJKHRHHDGSJEZ-UHFFFAOYSA-N 2-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethylisoquinoline-1,3-dione;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCN2C(C(C)(C)C3=CC=CC=C3C2=O)=O)CC1 SAJKHRHHDGSJEZ-UHFFFAOYSA-N 0.000 description 1
JNMUQWIITYQZSA-UHFFFAOYSA-N 2-methyl-4h-isoquinoline-1,3-dione Chemical compound C1=CC=C2C(=O)N(C)C(=O)CC2=C1 JNMUQWIITYQZSA-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
229920002972 Acrylic fiber Polymers 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
208000014311 Cushing syndrome Diseases 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
241001269524 Dura Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
206010030247 Oestrogen deficiency Diseases 0.000 description 1
206010033165 Ovarian failure Diseases 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000862969 Stella Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000006593 Urologic Neoplasms Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000008649 adaptation response Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000000695 adrenergic alpha-agonist Substances 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
229940126157 adrenergic receptor agonist Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000027455 binding Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000009956 central mechanism Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
150000004656 dimethylamines Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000009164 estrogen replacement therapy Methods 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
208000002566 gonadal dysgenesis Diseases 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000009097 homeostatic mechanism Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
102000055827 human SLC6A2 Human genes 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000009802 hysterectomy Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000022119 inability to concentrate Diseases 0.000 description 1
210000004283 incisor Anatomy 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229940116314 ketaject Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229930013053 morphinan alkaloid Natural products 0.000 description 1
208000008013 morphine dependence Diseases 0.000 description 1
229940024844 naloxone injection Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
235000003715 nutritional status Nutrition 0.000 description 1
WLGDAKIJYPIYLR-UHFFFAOYSA-N octane-1-sulfonic acid Chemical compound CCCCCCCCS(O)(=O)=O WLGDAKIJYPIYLR-UHFFFAOYSA-N 0.000 description 1
239000003401 opiate antagonist Substances 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
201000004535 ovarian dysfunction Diseases 0.000 description 1
231100000539 ovarian failure Toxicity 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000009955 peripheral mechanism Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
238000010149 post-hoc-test Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AU2004281750A 2003-10-14 2004-10-13 Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms Withdrawn AU2004281750A1 (en)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US51089703P	2003-10-14	2003-10-14
US10/685,812 US20040152710A1 (en)	2002-10-15	2003-10-14	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US60/510,897		2003-10-14
US10/685,812		2003-10-14
PCT/US2003/032759 WO2004035058A1 (fr)	2002-10-15	2003-10-15	Utilisation de modulateurs du recaptage de la noradrenaline en prevention et traitement de symptomes vasomoteurs
AUPCT/US2003/032759		2003-10-15
US10/962,897 US20050130987A1 (en)	2003-10-14	2004-10-12	Methods of treating vasomotor symptoms
US10/962,897		2004-10-12
PCT/US2004/033754 WO2005037260A2 (fr)	2003-10-14	2004-10-13	Procede de traitement de symptomes vasomoteurs

Publications (1)

Publication Number	Publication Date
AU2004281750A1 true AU2004281750A1 (en)	2005-04-28

Family

ID=34468478

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2004281750A Withdrawn AU2004281750A1 (en)	2003-10-14	2004-10-13	Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms

Country Status (4)

Country	Link
EP (1)	EP1846105A2 (fr)
AU (1)	AU2004281750A1 (fr)
MX (1)	MXPA06003866A (fr)
WO (1)	WO2005037260A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070021488A1 (en) *	2005-07-21	2007-01-25	Wyeth	Method for treating nervous system disorders and conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2345422C2 (de) *	1973-09-08	1983-12-22	Dr. Karl Thomae Gmbh, 7950 Biberach	Substituierte Isochinolyl-arylpiperazine diese enthaltende Arzneimittel sowie Verfahren zu deren Herstellung
US4310524A (en) *	1980-04-11	1982-01-12	Richardson-Merrell, Inc.	TCA Composition and method for rapid onset antidepressant therapy
US4302469A (en) *	1980-09-10	1981-11-24	Syntex (U.S.A.) Inc.	2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants
CA1327795C (fr) *	1987-08-14	1994-03-15	Jules Freedman	Antidepresseurs de type aryloxyindanamines
US20040152710A1 (en) *	2002-10-15	2004-08-05	Deecher Darlene Coleman	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) *	2002-10-15	2008-03-18	Wyeth	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) *	2002-10-15	2004-09-16	Deecher Darlene Coleman	Novel method of treating vasomotor symptoms

2004
- 2004-10-13 WO PCT/US2004/033754 patent/WO2005037260A2/fr not_active Ceased
- 2004-10-13 AU AU2004281750A patent/AU2004281750A1/en not_active Withdrawn
- 2004-10-13 EP EP04794977A patent/EP1846105A2/fr not_active Withdrawn
- 2004-10-13 MX MXPA06003866A patent/MXPA06003866A/es unknown

Also Published As

Publication number	Publication date
EP1846105A2 (fr)	2007-10-24
WO2005037260A3 (fr)	2007-08-16
WO2005037260A2 (fr)	2005-04-28
MXPA06003866A (es)	2006-07-03

Publication	Publication Date	Title
US20080227850A1 (en)	2008-09-18	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
RU2340333C2 (ru)	2008-12-10	Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции
US20040152710A1 (en)	2004-08-05	Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en)	2004-09-16	Novel method of treating vasomotor symptoms
US20120010260A1 (en)	2012-01-12	Method for treating nervous system disorders and conditions
US20050130987A1 (en)	2005-06-16	Methods of treating vasomotor symptoms
US20070021488A1 (en)	2007-01-25	Method for treating nervous system disorders and conditions
US20060020014A1 (en)	2006-01-26	Method for treating nervous system disorders and conditions
AU2004281750A1 (en)	2005-04-28	Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms
CA2539757A1 (fr)	2005-04-28	Utilisation d'antagonistes de recepteurs alpha-2b-adrenergiques pour traiter les symptomes vasomoteurs
CN101189043A (zh)	2008-05-28	肾上腺素能α2B拮抗剂用于治疗血管舒缩症状的应用

Legal Events

Date	Code	Title	Description
2009-09-03	MK12	Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal